BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 23536337)

  • 1. [New prospective on adjuvant treatment for gastrointestinal stromal tumors].
    Pan ZZ; Wu XJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):212-5. PubMed ID: 23536337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
    Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
    J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment progress of gastrointestinal stromal tumor].
    Ji X; Ji JF
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):292-6. PubMed ID: 23536354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
    López RL; del Muro XG
    Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New fronts in the adjuvant treatment of GIST.
    Reichardt P; Joensuu H; Blay JY
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):715-23. PubMed ID: 23934322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
    Li J; Dang YZ; Gao J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):216-20. PubMed ID: 23536338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presentation and management of gastrointestinal stromal tumours.
    Mongan AM; Malik V; Rowley S; Claxton Z; Muldoon C; O'Toole D; Ravi N; Reynolds JV
    Ir Med J; 2013 Jun; 106(6):176-9. PubMed ID: 23909154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing GIST in the imatinib era: optimization of adjuvant therapy.
    Trent JC; Subramanian MP
    Expert Rev Anticancer Ther; 2014 Dec; 14(12):1445-59. PubMed ID: 25340579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
    Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Application of perioperative imatinib mesylate therapy in initial resectable primary local advanced gastrointestinal stromal tumor at intermediate or high risk].
    Li SX; Li ZY; Zhang LH; Bu ZD; Wu AW; Wu XJ; Zong XL; Shan F; Ji X; Ji JF
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):226-9. PubMed ID: 23536340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant imatinib therapy for gastrointestinal stromal tumors.
    Pisters PW; Colombo C
    J Surg Oncol; 2011 Dec; 104(8):896-900. PubMed ID: 22069174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
    DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
    Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
    Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
    Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
    Jiang WZ; Guan GX; Lu HS; Yang YH; Kang DY; Huang HG
    J Surg Oncol; 2011 Dec; 104(7):760-4. PubMed ID: 21713778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model.
    Gold JS; Dematteo RP
    Ann Surg; 2006 Aug; 244(2):176-84. PubMed ID: 16858179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
    Sanon M; Taylor DC; Parthan A; Coombs J; Paolantonio M; Sasane M
    J Med Econ; 2013; 16(1):150-9. PubMed ID: 22762291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor: results of a population-based, matched-cohort study.
    Hatoum HT; Lin SJ; Sasane M; Trent JC
    Curr Med Res Opin; 2012 May; 28(5):805-14. PubMed ID: 22506625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy.
    Pandey R; Kochar R
    J Gastrointest Cancer; 2012 Dec; 43(4):547-52. PubMed ID: 22847491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidisciplinary care of gastrointestinal stromal tumour: a review and a proposal for a pre-treatment classification.
    Cananzi FC; Judson I; Lorenzi B; Benson C; Mudan S
    Eur J Surg Oncol; 2013 Nov; 39(11):1171-8. PubMed ID: 24063969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.